Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Pharmaceutical dealmaking slowed during the first half of 2026, yet industry experts say transaction quality has become more important than volume. Speaking with Pharmaceutical Technology, KPMG US Life Sciences Sector Leader Kristin Ciriello Pothier explained that manufacturers now place greater
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended Eli Lilly’s Jaypirca (pirtobrutinib) for approval to treat adults with chronic lymphocytic leukemia (CLL) across all lines of therapy, regardless of previous BTK inhibitor treatment. The
Mayo Clinic is applying artificial intelligence across its revenue cycle operations to streamline repetitive administrative workflows, while maintaining human oversight in clinical and billing decisions. Revenue cycle chair Todd Manion shared these insights during an interview at HFMA’s annual conference
The cell and gene therapy (CGT) industry is facing growing pressure to transform how it develops, manufactures, and commercializes advanced therapies, according to industry experts speaking ahead of BIO 2026. In discussions highlighted by BioSpace on June 22, 2026, leaders
Biopharmaceutical industry confidence reached a four-year high in early 2026, according to GlobalData’s State of the Biopharmaceutical Industry 2026 Mid-Year Update, based on a survey of 157 professionals. The report shows 55% of respondents are optimistic about growth despite geopolitical
Pharma dealmaking slowed in early 2026 as buyers tightened valuation discipline and increased diligence across life sciences transactions. AI partnerships, manufacturing acquisitions, and oncology consolidation are shaping the next phase of pharma deal activity, with recovery expected in late 2026
The Food and Drug Administration has introduced its Commissioner’s National Priority Voucher (CNPV) pilot program to accelerate drug and biologic review timelines in the United States. According to industry analysis by Lifescience Dynamics, the program aims to reduce approval timelines
Pharmaceutical Executive Daily reports that the FDA Vaccines and Related Biological Products Advisory Committee unanimously voted 9–0 in favor of Moderna’s investigational mRNA-1010 seasonal influenza vaccine for adults aged 50–64 and 65+. The committee confirmed that the benefit-risk profile supports
At ASCO 2026 in Chicago, Daiichi Sankyo R&D chief John Tsai outlined a long-term strategy to expand antibody-drug conjugate innovation using AI and data-driven biology. The company plans to build at least two new ADC platforms by 2030 while facing
As layoffs continue across parts of the biopharma industry in 2026, experts say workforce reductions rarely happen without warning. While many employees focus on cost-cutting measures, industry leaders believe the strongest signals often come from clinical progress, pipeline strategy and